Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Average Rating of “Buy” from Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has earned a consensus rating of “Buy” from the five brokerages that are presently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have covered the stock in the last year is $36.60.

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Evercore ISI boosted their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. increased their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA opened at $22.04 on Wednesday. The business has a fifty day moving average price of $24.23 and a 200-day moving average price of $22.91. The company has a market capitalization of $1.59 billion, a PE ratio of -157.42 and a beta of 0.35. Kiniksa Pharmaceuticals has a 1-year low of $15.52 and a 1-year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The firm had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm’s revenue for the quarter was up 67.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.20) earnings per share. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total value of $1,585,275.04. Following the transaction, the insider now directly owns 52,038 shares in the company, valued at approximately $1,359,232.56. This trade represents a 53.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total transaction of $456,790.00. Following the transaction, the chief operating officer now owns 109,975 shares in the company, valued at $2,955,028.25. This represents a 13.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 95,192 shares of company stock valued at $2,479,390 over the last 90 days. Company insiders own 54.57% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of KNSA. Braidwell LP raised its stake in shares of Kiniksa Pharmaceuticals by 40.6% in the third quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock worth $72,334,000 after buying an additional 836,210 shares during the period. FMR LLC increased its holdings in Kiniksa Pharmaceuticals by 36,925.0% in the 3rd quarter. FMR LLC now owns 696,810 shares of the company’s stock worth $17,413,000 after acquiring an additional 694,928 shares in the last quarter. Millennium Management LLC raised its stake in Kiniksa Pharmaceuticals by 159.8% during the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after acquiring an additional 382,539 shares during the period. Jane Street Group LLC lifted its holdings in Kiniksa Pharmaceuticals by 1,064.4% during the third quarter. Jane Street Group LLC now owns 345,092 shares of the company’s stock valued at $8,624,000 after purchasing an additional 315,456 shares in the last quarter. Finally, Rubric Capital Management LP boosted its position in shares of Kiniksa Pharmaceuticals by 10.2% in the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after purchasing an additional 223,094 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.